Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-B for Initially Unresectable Colorectal Liver Metastases
NCT00508872Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2005
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in colorectal liver metastases (CRLM), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2005; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT00508872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508872.